Latest news with #Libre
Daily Mirror
5 days ago
- Business
- Daily Mirror
Estée Lauder perfume that smells 'oriental and enchanting' is reduced to £41
If you're looking for a new signature perfume, Amazon has just slashed the price of Estée Lauder's iconic fragrance that shoppers have loved for decades Payday is just around the corner for most of us, and what a better way to spend your hard-earned paycheck than on a little luxury treat for yourself? If you're looking for the perfect payday pick or are just in need of a new fragrance for the summer, we've found just the one. Estée Lauder's Cinnnabar Eau De Parfum has been praised by shoppers for being 'beautifully oriental and enchanting', and the best part is that it's currently reduced on Amazon in a limited time offer. Originally priced at £49 on Amazon, but £70 on the Estée Lauder wesbite, a flash sale sees this fragrance drop down to £41. If you're after a perfume that's warm, fresh and a little spicy, Cinnabar is the perfect scent. With opening notes of jasmine, orange flower and tangerine, there's a citrusy freshness to the fragrance. This is then followed with rich base notes of olibanum, patchouli, sandalwood and clove. The result? A sensual and warming fragrance that will linger all day. Shoppers can't get enough of this perfume, with someone raving that they've been using the scent for the past 20 years. They wrote: "This is truly an unforgettable Scent. It is as beautifully oriental and enchanting Today as the first day I was given it on my 21st Birthday in the late 1990's. A lovely new box and bottle added to the experience." And a second added: "Love this perfume been using it for over 40+ years and the compliments I get every time is insane. Fabulous quality and at a knocked down price too". However, not everyone is as fond of Cinnabar as they once were, with a few stating that since Estée Lauder tweaked the formula, it doesn't last quite as long and doesn't have the same punchy fragrance. One shopper said: "I've worn this perfume since the early 80sI Bought a bottle last year in the new packaging...I contacted Estée Lauder only to discover they've changed the formula!" If you're looking for a similar fragrance, a few have likened the scent to YSL's Black Opium, which is currently reduced on LookFantastic from £69 to £55.20. While my personal favourite YSL perfume is the Dua Lipa-fronted Libre, also on sale for £57.60 down from £72.
Yahoo
5 days ago
- Business
- Yahoo
Should You Continue to Retain Abbott Stock in Your Portfolio Now?
Abbott ABT is witnessing increased global demand for routine diagnostic tests over the past few quarters. The Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. Within Established Pharmaceuticals ('EPD'), the company is driving robust growth in key therapeutic areas and advancing in the biosimilar strategy. However, macroeconomic impacts and adverse currency fluctuations may hurt Abbott's financial performance. In the past year, this Zacks Rank #3 (Hold) stock has rallied 26.4% compared with the 9% rise of the industry and 8.8% growth of the S&P 500 composite. The healthcare giant has a market capitalization of $231.38 billion. The company's earnings yield of 3.9% is well above the industry's 0.5%. Abbott surpassed estimates in three of the trailing four quarters and broke even in one, delivering an average earnings surprise of 1.6%. Strong Prospects Within Core Diagnostics: Abbott continues to expand its Diagnostics business foothold (consisting of 20% of the total revenues in the first quarter of 2025). The company is particularly gaining from strong demand for its portfolio of respiratory disease tests used to help diagnose influenza, strep throat and respiratory syncytial virus. Abbott is witnessing the adoption of these platforms under a variety of settings, including hospitals, laboratories, urgent care centers, physician offices, retail pharmacies and blood screening facilities. Image Source: Zacks Investment Research Core Laboratory Diagnostics, excluding China, posted solid 6.5% growth in the first quarter of 2025, highlighting the underlying strength in routine diagnostics demand across global markets. Looking forward, Abbott's $0.5 billion investment in new manufacturing and R&D facilities in Illinois and Texas aims to expand its U.S. transfusion diagnostics business. Moreover, the upcoming launch of the Alinity m system marks Abbott's entry into the molecular nucleic acid testing segment — a $1 billion market opportunity. Libre Drives Diabetes Care: Of late, the company has been fast gaining momentum, leveraging consistent upgrades of FreeStyle Libre. Earlier in 2024, Abbott obtained FDA approvals for two new over-the-counter continuous glucose monitoring systems called Lingo and Libre Rio, which are based on Libre's technology, which is now used by more than 6 million people around the world. This over-the-counter availability of CGM marks the initiation of a new era in the United States for Abbott. In the first quarter, in Diabetes Care, sales of CGM exceeded $1.7 billion and grew 21.6%. Several products contributed to the strong performance, including FreeStyle Libre, Navitor, TriClip, Amplatzer Amulet and AVEIR. EPD Set for Sustainable Growth: Abbott's EPD operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these growing pharmaceutical markets. In the first quarter of 2025, EPD sales increased 8% organically. More than half of its top 15 markets posted double-digit gains. Abbott's strategic focus on biosimilars strengthens its prospects, with the company now securing rights to 15 biosimilar products across key therapeutic areas. The recent agreement to commercialize four additional biosimilars across Asia, Latin America, the Middle East and Africa positions Abbott to tap into the high-growth branded generic pharmaceutical market. Choppy Macro Environment to Weigh on Margins: The challenging macroeconomic scenario in the form of the ongoing complex geopolitical situation globally, trade war specifically with countries where Abbott operates, is driving a higher-than-anticipated increase in expenses in terms of raw materials and freight. Industry-wide, it has been seen that the deteriorating global economic environment is reducing demand for several MedTech products, resulting in lower sales and lower product prices while increasing the cost of goods and operating expenses of the businesses of MedTech companies. Foreign Exchange Translation Impacts Sales: Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company's performance in the international markets. In the first quarter of 2025, foreign exchange had an unfavorable year-over-year impact of 2.8% on sales. In the past 30 days, the Zacks Consensus Estimate for ABT's 2025 earnings has remained constant at $5.16 per share. The Zacks Consensus Estimate for the company's 2025 revenues is pegged at $44.68 billion, suggesting a 6.5% rise from the year-ago reported number. Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. Phibro Animal Health has an estimated long-term earnings growth rate of 26% compared with the industry's 15.7%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 30.6%. Its shares have rallied 39.5% compared with the industry's 9% growth in the past year. PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Hims & Hers Health, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 1.3% against the industry's -10.1% yield. Shares of the company have surged 81.2% compared with the industry's 40.1% gain. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched on one occasion and missed on another, the average surprise being 2.8%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 3.8%. Shares of the company have rallied 23% against the industry's 17.2% decline. COR's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Record
17-06-2025
- Entertainment
- Daily Record
'I worked at Boots and this little known perfume may be the scent of summer'
For the perfume fans among us, summer always presents an opportunity to find a new scent. With so many bottles on the market, many of us go for ones that are well known. However, amongst the Marc Jacobs and Hugo Boss offerings that tend to be bestsellers at this time of year, there are a few alternative options amongst them that are worth giving a go. One of them is the newly launched Zadig, by Parisian fragrance house, Zadig & Voltaire, a 'floriental woody fragrance for women' that, despite being a new addition to the market, has already earned glowing praise from one perfume fanatic. Bethan Shufflebotham of the Manchester Evening News, who used to work on the health and beauty chain's perfume counter, spotted this light, creamy coloured perfume on a recent store visit and said she "didn't know whether to shout about it from the rooftops, or keep it a closely guarded secret." After she couldn't resist spritzing the perfume, which boasts a unique wing-inspired bottle, the former Boots employee shared her full thoughts which can be found just below. "The result is a warm, smoky and incredibly moreish scent you can't help but keep going back to. It's feminine but powerful and a little edgy, like those cool girls that pull off a leather jacket thrown over a silk slip dress. "When I look at my perfume collection, it is pretty vanilla heavy, which is perhaps why I was so drawn to Zadig. According to perfume experts on TikTok, fragrances with similar profiles will tend to be housed in a bottle of a similar colour, which is a hack that comes in super handy when shopping fragrances online, or if you don't want to smell every bottle in store to find something you like. "With that theory in mind, some alternatives may include the likes of YSL Libre, which also contains orange blossom and vanilla. Zadig also says their wing-inspired bottle is symbolic of freedom, with Libre translating to 'free' in French. " Burberry Goddess would be another great choice, boasting key notes of vanilla and lavender. And coincidentally, Amandine Clerc-Marie was involved in crafting this popular 2023 scent, too. Despite being new to the market, Zadig is already holding its own, and has gained popularity with fans of Alien, Flowerbomb and Fame. One said: 'I'm usually quite pernickety about sweet fragrances but this was not overpowering at all. In fact I was regularly complimented when wearing it. It's a bit more tart than YSL Black Opium but I quite like that.' 'This is one of the best perfumes I've smelt in a while,' said another. 'It has a gorgeous fragrance and lasts all day. Quite a few people have commented when I wear it, I absolutely love it.' A third penned: 'Absolutely loved this. Gorgeous bold smell and really did last all day from one squirt. Usually wear Flowerbomb and this is a good rival for similar scent, but this is the longest lasting I've ever found.' The fragrance is also vegan and made from 89% natural-origin ingredients, plus the bottle is refillable, making it more sustainable than some other bottles available. However, some shoppers weren't so keen on the wing design. 'I absolutely love the scent of this fragrance. At first it smells quite strong but becomes subtle quite quickly, however I could still smell it on me 5+ hours later. I'm not a big fan of the statement bottle, which is why it's lost a star from me.' While the scent profile has earned much praise, some wearers (as above) report it lasting five plus hours, others note that it fades more quickly. Beauty deal of the week Looking for last minute gift inspiration for dad ahead of Sunday, June 15. Then don't fret, as we have you covered, as no-one can go wrong with a new bottle of cologne, and we have spotted Versace's The Dreamer for him Eau de Toilette for 67 percent less at Superdrug. Hailed for being "underrated" and "truly unique", a large 100ml bottle of this fragrance has been dropped from £74 to £24, allowing you to make a huge saving of £50 and get in a thoughtful gift. Described as "warm" and "fresh", Versace's Dreamer is an aromatic fragrance that, while belonging to the cologne family, is said to boast a variety of notes that make it suitable for both men and women. The scent opens on vibrant notes of juniper, tarragon, and artemisia, before blending into heart notes of iris, lily and flax flowers to add a touch of softness. It then ends on a comforting base of tobacco blossom and amber, offering a smoky, luxurious finish. The transparent, clear fragrance itself is housed in an opulent glass bottle that has been embossed with the iconic medusa logo, representing the luxury aesthetic of the iconic fashion house. Versace's Dreamer EDT has managed to earn glowing reviews and a 4.6 rating from shoppers, with one saying: "Truly unique and dreamy fragrance. It's a great fragrance but it's underrated. Guys you have to try this one, it's great for all year round." And someone else wrote: "Not to be overlooked. This is a lesser known Versace men's fragrance but oh my it is gorgeous ! Hubby loved it and amazing value for money." Versace's The Dreamer For Him Eau de Toilette (100ml) can be bought for 67 percent less at Superdrug now. One shopper who usually wears Fame or Alien said: 'Upon spraying a bit onto a sample stick I was not expecting to be wowed at all. How wrong I was. It smelled amazing. "Very reminiscent of my beloved long time signature scent of Alien. So I doused myself in the stuff before leaving the store. Went home and straight onto Boots online. "Decided to order myself the biggest bottle as best value for money. It's also refillable which also scores big brownie points with me. I've worn it once since it arrived and received many compliments on my scent and I've told everyone about 'Zadig''. Finishing her own review, Bethan added: "I will be honest I'd never heard of the brand or the perfume itself until I happened by it accidentally. I am saving mine for special occasions so as not to overwear it. "My only niggle is that I don't think the scent lasts all day as I couldn't smell it after a few hours unlike Alien and Fame. So even though it was a perfume as opposed to an EDT I feel they need to work on the longevity of the wear somehow." Perfume fans looking to try out the little known Zadig & Voltaire - ZADIG Eau de Parfum (90ml) can buy it for £110 from Boots now.
Yahoo
16-06-2025
- Business
- Yahoo
Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth
-- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid rising adoption in both type 1 and type 2 diabetes patients. The firm started Dexcom (NASDAQ:DXCM), Insulet (NASDAQ:PODD), and Beta Bionics with Buy ratings, while initiating Tandem Diabetes Care (NASDAQ:TNDM) at Hold. Truist already covers Medtronic's diabetes business, which it rates 'Hold.' Truist said the diabetes device sector is positioned for double-digit growth over the next several years, driven by expanding use in underpenetrated global markets and a shift toward more patient-centric care. Survey feedback from physicians suggested stronger adoption of pumps and CGMs in type 2 diabetes, particularly among patients using insulin. Among the large-cap names, the firm favored Dexcom and Insulet, citing strong profitability and leadership in the growing CGM and patch pump segments. While Truist said that Insulet's recent CEO change may introduce some near-term uncertainty, it said the company's growth trajectory remains intact. Dexcom, which has faced concerns following mid-2024 execution missteps and rising competition from Abbott's Libre system, still offers a favorable risk-reward, Truist said, pointing to a lower relative valuation and catalysts such as guideline updates and expanding reimbursement for type 2 diabetes. In the small-cap space, Truist preferred Beta Bionics over Tandem. It noted both firms face challenges in the slower-growing durable pump market but said Beta Bionics' iLet system has a potential ease-of-use advantage and a head start in transitioning to more profitable pharmacy distribution channels. Regarding potential volatility in shares of both Beta Bionics and Tandem, Truist said the broader diabetes device market remains one of the most attractive growth areas in medtech, supported by technology innovation, evolving reimbursement, and increased patient engagement. Related articles Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth Boeing Commercial Airplanes head meets Air India chairman after fatal 787 crash Forward Air stock surges on report PE firms express acquisition interest
Yahoo
24-05-2025
- Business
- Yahoo
Was Jim Cramer Right About Abbott Laboratories (ABT)?
We recently published a list of . In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 20, a caller asked whether to hold or buy more shares of Abbott Laboratories (NYSE:ABT), amid a pending lawsuit over baby formula. Cramer remained positive on the outlook but advised waiting for a lower entry. 'The outlook is fabulous. There is a lawsuit in July involving formula — its competitor Reckitt Benckiser lost a case. I think that this is not going to be a big deal. But it doesn't matter — people know what happened with J&J and they're scared. We're waiting till at least it gets to par or 100 to be able to buy more. But we believe in the company.' Abbott Laboratories delivered steady growth with a 28.54% gain, justifying his patient buy-on-dip approach. Abbott Laboratories (NYSE:ABT) is rebounding as its diversified healthcare products and diagnostics tools see renewed investor interest. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Discussing the stock's valuation, Cramer gave the following analysis in May this year: 'Okay, their forward PE shows that there's going to be a, pretty much of an earnings explosion. And I think a lot of that's going to be coming from Libre, which is their diabetes, they have the best diabetes device. It's cheaper than everybody's. Overall, ABT ranks 2nd on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
